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Abstract 164 
Background: The treatment gap between the number of people with mental disorders and the 165 
number treated represents a major public health challenge. We examine this gap by socio-166 
economic status (SES; indicated by family income and respondent education) and service sector 167 
in a cross-national analysis of community epidemiological survey data.  168 
Methods: Data come from 16,753 respondents with 12-month DSM-IV disorders from 169 
community surveys in 25 countries in the WHO World Mental Health Survey Initiative. DSM-IV 170 
anxiety, mood, or substance disorders and treatment of these disorders were assessed with the 171 
WHO Composite International Diagnostic Interview (CIDI).  172 
Results: Only 13.7% of 12-month DSM-IV/CIDI cases in lower-middle-income countries, 173 
22.0% in upper-middle-income countries, and 36.8% in high-income countries received 174 
treatment. Highest-SES respondents were somewhat more likely to receive treatment, but this 175 
was true mostly for specialty mental health treatment, where the association was positive with 176 
education (highest treatment among respondents with highest education and a weak association 177 
of education with treatment among other respondents) but non-monotonic with income 178 
(somewhat lower treatment rates among middle-income respondents and equivalent among those 179 
with high and low incomes).  180 
Conclusions: The modest, but nonetheless stronger, association of education than income with 181 
treatment raises questions about a financial barriers interpretation of the inverse association of 182 
SES with treatment, although future within-country analyses that consider contextual factors 183 
might document other important specifications. While beyond the scope of this report, such an 184 
expanded analysis could have important implications for designing interventions aimed at 185 
increasing mental disorder treatment among socio-economically disadvantaged people. 186 
7 
 
 187 
Key words: Mental disorders, mental health service use, inequalities, education, income, 188 
occupation, WMH surveys, population studies 189 
190 
8 
 
Background 191 
The discrepancy between the number of people needing treatment for mental disorders 192 
and the number receiving treatment, known as the mental health treatment gap, represents a 193 
major public health challenge. Although mental disorders are a leading cause of disability 194 
(World Health Organization, 2012; Whiteford et al. 2015; Vigo et al. 2016), only a minority of 195 
people with these disorders receives treatment (Wang et al. 2007). This gap is even greater for 196 
people with low socio-economic status (SES) and those living in low-income countries (Steele et 197 
al. 2007; Ormel et al. 2008) even adjusting for disorder severity (Mojtabai, 2010; Andrade et al. 198 
2014).  199 
It is less clear, though, whether these disparities are equally large across all service 200 
sectors and all levels of disorder severity. We know that cross-national differences in treatment 201 
rates are strongly influenced by healthcare spending (Lewer et al. 2015) and that probability of 202 
receiving treatment is influenced by illness severity (Wang et al. 2007). We also know that 203 
specialist mental health (SMH) treatment resources are scarcer than general medical and 204 
nonmedical resources and that access to SMH treatment is often restricted through gatekeepers to 205 
the most severe-complex cases (Thornicroft & Tansella, 2013). It is less clear, though, how much 206 
the association of SES with treatment varies with these other factors. SES might be more weakly 207 
associated with treatment among severe cases or in the SMH sector due to access being driven 208 
more by need than ability to pay. Alternatively, it might be that the association of SES with 209 
treatment is stronger in these cases due to more stringent barriers associated with low-SES. 210 
Research on more general patterns of healthcare utilization suggests that the latter is the case: 211 
that is, that under-representation of low-SES individuals is more pronounced in the specialty 212 
sector than general medical sector (Devaux & De Looper, 2012), but this pattern might not hold 213 
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for mental disorders. Nor do we know how stable such a pattern is across countries, although 214 
there is some evidence of cross-national differences in the association of SES with mental 215 
disorder treatment (Kessler et al. 1997; Van Doorslaer & Masseria, 2004; Devaux & De Looper, 216 
2012).  217 
The World Mental Health (WMH) Surveys (Kessler et al. 2009), a series of cross-218 
sectional population surveys of common mental disorders, provide an unprecedented opportunity 219 
to investigate the SES gradient in treatment of mental disorders at the level of the individual 220 
survey respondent as a joint function of disorder severity, service sector, and country income 221 
level. We do this here focusing on mental disorders in the 12 months before interview. It is 222 
noteworthy that the cross-national interactions we consider are at the level of the country income 223 
group rather than individual country in order to maintain precision in estimating individual-level 224 
coefficients. It might be that future analyses could gain more insight by investigating contextual 225 
factors other than country income level, but we considered this the most interesting broad factor 226 
discriminating WMH countries the current analysis.  227 
Methods 228 
Sample 229 
 Data come from the 16,753 respondents across 28 WMH surveys with 12-month DSM-230 
IV disorders. The surveys were administered to representative samples of adult household 231 
residents in 25 countries. These include 7 surveys from countries classified by the World bank as 232 
lower-middle-income (Colombia, Iraq, Nigeria, Peoples Republic of China, Peru, Ukraine), 7 233 
upper-middle-income (Brazil, Bulgaria, Medellin Colombia [carried out at a later date than the 234 
national Colombian survey, at which time the income level of the country had increased], 235 
Lebanon, Mexico, Romania, South Africa), and 14 high-income (Belgium, France, Germany, 236 
10 
 
Israel, Italy, Japan, Netherlands, New Zealand, Northern Ireland, Poland, Portugal, Spain [both a 237 
national survey and regional survey in Murcia], USA) (World Bank, 2009). There were no low-238 
income countries in the sample.  239 
The samples were based on a multi-stage clustered area probability household design. 240 
Samples were nationally representative in 19 surveys, representative of all urbanized areas in 3 241 
others (Colombia, Mexico, Peru), and representative of selected regions (Nigeria) or 242 
Metropolitan areas (Sao Paulo in Brazil, Medellin in Colombia, a series of cities in Japan, 243 
Beijing/Shanghai and Shenzhen in the Peoples Republic of China) in the others. More details on 244 
sample designs are presented in Appendix Table 1. Interviews were carried out face-to-face in 245 
respondents’ homes by trained lay interviewers. The respondents considered here were aged 18 246 
and over other than in Medellin (age 19), Japan (age 20), and Israel (age 21). Response rates 247 
were 45.9-97.2% across surveys with a weighted (by sample size) average of 70.1% using the 248 
American Association for Public Opinion research RR1w definition (AAPOR, 2016).  249 
 To reduce respondent burden, interviews were divided into two parts. Part I assessed core 250 
mental disorders and was administered to all respondents. Part II assessed additional disorders 251 
and correlates and was administered to all Part I respondents with any Part I disorder plus a 252 
probability subsample of other Part I respondents. Part II data were weighted to adjust for the 253 
under-sampling of Part I non-cases, making weighted Part II prevalence estimates identical to 254 
Part I estimates. Treatment was assessed in Part II. 71,239 Part II respondents were interviewed 255 
across all surveys, 16,753 of whom met criteria for any 12-month disorders. These 12-month 256 
cases are the focus of analysis here. Further details about WMH weighting are available 257 
elsewhere (Heeringa et al. 2008).  258 
Measures 259 
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 Mental disorders: Mental disorders were assessed with the WHO Composite 260 
International Diagnostic Interview (CIDI) Version 3.0 (Kessler & Ustun, 2004), a fully-261 
structured interview generating lifetime and 12-month prevalence estimates of common DSM-IV 262 
disorders. The 12 disorders considered here include 7 anxiety disorders (adult separation anxiety 263 
disorder, agoraphobia, generalized anxiety disorder, panic disorder, post-traumatic stress 264 
disorder, social phobia, specific phobia), 3 mood disorders (bipolar disorder including bipolar I, 265 
II and sub-threshold; dysthymic disorder; major depressive episode [MDE]), and 2 substance use 266 
disorders (abuse or dependence on alcohol or illicit drugs). As detailed elsewhere (Merikangas et 267 
al. 2011), our definition of sub-threshold bipolar disorder includes both hypomania without 268 
history of major depressive episode and sub-threshold hypomania with history of major 269 
depressive episode. Our definition of substance dependence is limited to cases with a history of 270 
abuse. The CIDI interview translation, back-translation, adaptation, and harmonization protocol 271 
required culturally competent bilingual clinicians to review, modify, and approve key phrases 272 
describing symptoms (Harkness et al. 2008). Blinded clinical reappraisal interviews with the 273 
Structured Clinical Interview for DSM-IV (First et al. 2002) in a number of WMH surveys found 274 
generally good concordance with diagnoses based on the CIDI (Haro et al. 2006).  275 
 We focus here on disorders present in the 12 months before interview. Respondents were 276 
classified as having a severe 12-month disorder if at least one of their DSM-IV/CIDI disorders 277 
included either bipolar I disorder, substance dependence with a physiological dependence 278 
syndrome, any disorder associated with making a 12-month suicide attempt, or any disorder 279 
associated with severe impairment in any domain of the expanded-revised Sheehan Disability 280 
scales (SDS) (Leon et al. 1997). Respondents not classified severe were classified moderate if at 281 
least one of their 12-month disorders included substance dependence without a physiological 282 
12 
 
dependence syndrome or at least one disorder with moderate interference in any SDS domain. 283 
All other respondents with 12-month disorders were classified as mild (Ten Have et al. 2013).  284 
Mental Health Treatment: Part II respondents were asked if they ever obtained 285 
professional treatment for “problems with emotions, nerves, mental health, or use of alcohol or 286 
drugs” and, if so, whether they received such treatment at any time during the 12 months before 287 
interview. Importantly, this question was not disorder-specific, which means that we have no way 288 
of knowing which disorders respondents sought treatment for. Respondents who reported 12-289 
month treatment were asked whether they received this treatment during the past 12 months from 290 
each of a wide range of treatment providers that were subsequently classified into four 291 
categories: (1) specialist mental health (SMH; psychiatrist, psychologist, other mental health 292 
professional in any setting, social worker or counselor in a mental health specialist treatment 293 
setting, used a mental health hotline); (2) general medical (GM; primary care doctor, other 294 
medical doctor, any other healthcare professional seen in a GM setting); (3) human services (HS; 295 
religious or spiritual advisor, social worker, or counsellor in any setting other than SMH); and 296 
(4) complementary alternative medicine (CAM; any other type of healer such as chiropractors or 297 
participation in self-help groups). Further details on the treatment variables are presented 298 
elsewhere (Wang et al. 2007).  299 
 Socio-economic status: Two indicators of SES were considered: respondent education 300 
and family income in the 12 months before interview. As educational levels and systems varied 301 
across countries, education was defined in terms of four groups based on country-specific 302 
distributions of high (which, in high-income countries, corresponded to a college degree with or 303 
without further education), high-average (some post-secondary education without a college 304 
degree), low-average (secondary school graduation), and low (less than secondary education, 305 
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including no education). More details on the education coding scheme are presented elsewhere 306 
(Scott et al. 2014). Family income was also divided into four categories using the within-country 307 
approach adopted in international studies of welfare economics (Levinson et al. 2010), which 308 
defines high income as greater than three times the within-country median per capita family 309 
income (i.e., income divided by number of family members), high-average income as between 310 
one and three times median per capita family income, low-average income as 50-100% of 311 
median per capita family income, and low income as less than or equal to 50% of median per 312 
capita family income.  313 
Control variables: Our models controlled for respondent age, sex, and marital status. 314 
Age was considered in four groups of 18-34, 35-49, 50-64, and 65+. Marital status was divided 315 
into three groups of never married, previously married (separated, divorced, widowed), and 316 
currently married or cohabiting. 317 
Statistical analysis 318 
 Weights adjusted for under-sampling Part I respondents without disorders, differences in 319 
within-household probabilities of selection (due to the selection of only one respondent per 320 
household no matter the number of eligible residents), and residual discrepancies between 321 
sample and population distributions on Census demographic-geographic variables. All 322 
multivariable regression models in these weighted data were estimated in pooled cross-national 323 
analyses with dummy control variables included for surveys, yielding coefficients representing 324 
pooled within-survey associations. Controls were also included for respondent age, sex, and 325 
marital status. 326 
The multivariate associations of type, number, and severity of mental disorders with 327 
treatment were specified in a relatively complex model, both because these disorder 328 
14 
 
characteristics are known to predict treatment (Andrade et al. 2014) and because SES is known 329 
to be inversely related to these disorder characteristics (Scott et al. 2014), making it important to 330 
control adequately for these characteristics to obtain accurate estimates of effects of SES on 331 
treatment. Expanded models then examined both main effects of SES and interactions of SES 332 
with disorder severity and country income level. All models were estimated using a logistic link 333 
function. 334 
The multivariable associations of mental disorders with treatment in these models were 335 
necessarily constrained because the number of logically possible disorder combinations (212 = 336 
4,096) is far greater than the number of predictors we could include in the models. As a result, 337 
our models included 12 separate disorder-specific dummy variables along with dummy variables 338 
for exactly 3 and 4+ disorders. Given that all respondents had at least one disorder and that the 339 
model included dummy variables for people with 3+ disorders, the disorder-specific ORs 340 
represent the adjusted (for the control variables) incremental predicted odds of treatment (versus 341 
not-treatment) among respondents with exactly one disorder. The incremental predictive effects 342 
of individual disorders among people with 2 disorders were then assumed to be multiplicative; 343 
that is, if the OR associated with Disorder X was 1.5, we would expect respondents with exactly 344 
1 other disorder would have a 1.5 increased odds of obtaining treatment in the presence versus 345 
absence of Disorder X. This specification imposed parsimony on the data by constraining the OR 346 
of Disorder X to be the same across all 11 combinations of Disorder X with exactly l other 347 
disorder (i.e., reducing the 12 x 12 = 144 logically possible main effects and 2-way interactions 348 
between pairs of disorders to 12 coefficients). The dummy variables for 3 and 4+ disorders 349 
imposed additional constraints by assuming that the 3-way and higher-order interactions among 350 
disorders predicting treatment were subject to a constant multiplier that could be 1.0 (i.e., the 351 
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interactions were strictly multiplicative) or different from 1.0. Models of this form have been 352 
shpwn to be useful in a number of prior WMH analyses (e.g., Stein et al. 2016; McGrath et al. 353 
2016).  354 
Logistic regression coefficients and standard errors were exponentiated to generate odds-355 
ratios (ORs) and 95% confidence intervals (95% CIs). Confidence intervals for prevalence 356 
estimates and ORs were estimated using the Taylor series linearization method (Wolter, 1985) 357 
implemented in the SUDAAN software system (Research Triangle Institute, 2002) to adjust for 358 
weighting and geographic clustering of data. We used design-based F tests to evaluate between 359 
country differences in means and design-based Wald 2 tests to evaluate the multivariable 360 
significance of predictor sets to decide when individually significant coefficients should be 361 
interpreted. Significance was consistently evaluated using .05-level two-sided tests. Even with 362 
these global tests, though, over-fitting was possible due to the large number of tests, making it 363 
important to consider results only exploratory.  364 
Results 365 
Twelve-month treatment of DSM-IV/CIDI disorders 366 
 A weighted 14.9% of Part II respondents across surveys met criteria for at least one 12-367 
month DSM-IV/CIDI disorder. More details about between-survey differences and prevalence 368 
estimates of individual disorders are reported elsewhere (Scott et al. In press). 29.0% of 369 
respondents with 12-month disorders received 12-month treatment. The treatment rate was 370 
highest in high-income countries (36.8%), lower in upper-middle-income countries (22.0%), and 371 
lowest in lower-middle-income countries (13.7%; F2,5366=221.1, p<.001). (Table 1) The highest 372 
treatment rate across surveys was in Murcia, Spain (49.6%) and the lowest in Shenzhen in the 373 
People’s Republic of China (PRC; 6.7%).  374 
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(Table 1 about here)  375 
 The GM sector had the highest treatment rate (17.8%). The SMH sector had the second 376 
highest treatment rate (13.5%). The treatment rates were much lower in the human services 377 
sector (3.7%) and CAM sector (3.7%). The sum of sector-specific treatment rates (38.7/100 378 
respondents) exceeded the 29.0% of individuals with any treatment due to some patients being 379 
treated in multiple sectors. Although there was a consistent trend for treatment rates to decrease 380 
with country income level within each sector ((F2,5366=132.7, p<.001 for SMH; F2,5366=231.4, 381 
p<.001 for GM; F2,5366=6.0, p=.003 for HS; F2,5366=33.2, p<.001 for CAM) as well as overall 382 
(F2,5366=221.1, p<.001), treatment was consistently most common in the GM sector followed by 383 
the SMH sector and much lower in the human services and CAM sectors. 384 
Clinical predictors of treatment  385 
Disorder type was significant in predicting treatment in the base multivariate model 386 
predicting overall treatment (12=506.1, p<.001) as well as treatment in each service sector 387 
(12=36.4-315.1, p<.001). (Table 2) The significant disorder-specific ORs were overwhelmingly 388 
greater than 1.0, indicating that comorbidity was associated with increased odds of treatment. 389 
Generalized anxiety disorder and PTSD had significantly elevated ORs in all 5 equations 390 
(OR=1.4-2.0). Major depressive episodes had significantly elevated ORs in 4 equations 391 
(OR=1.5-2.4), the exception being human services treatment. Two disorders had significantly 392 
elevated ORs predicting any treatment and treatment in the SMH and GM sectors: panic 393 
disorders (OR=2.4-3.4) and agoraphobia (OR=1.6-1.9). Drug use disorder had significantly 394 
elevated ORs predicting any treatment and treatment in the SMH and CAM sectors (OR=1.6-395 
1.8). And two disorders, social phobia and bipolar spectrum disorder, had significant ORs 396 
predicting treatment in the SMH sector (OR=1.2-1.3). Alcohol use disorder was the only disorder 397 
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associated with multiple significantly decreased ORs, which involved any treatment and 398 
treatment in the GM and human services sectors (OR=0.6-0.7) indicating that respondents with 399 
any other disorder profiles were significantly less likely to obtain treatment in these sectors in the 400 
presence than absence of comorbid alcohol use disorder.  401 
(Table 2 about here)  402 
Disorder number was significantly associated with each type of treatment (2=9.4-11.7, 403 
p =.003-.009) due to significantly decreased ORs for 4+ disorders (OR=0.6-0.7). These 404 
decreased ORs indicate that the elevated odds of treatment due to comorbidity (i.e., the generally 405 
positive sign pattern of disorder-specific ORs) increase at a decreasing rate as comorbidity 406 
becomes more complex. Disorder severity, finally, had a significant monotonic relationship with 407 
Each treatment outcome (2=21.3-186.0, p<.001), with severe disorders having highest relative-408 
odds (OR=2.0-2.9) followed by moderate disorders (OR=1.3-1.5) compared to mild disorders.  409 
SES differences in treatment  410 
  The 4-category measures of respondent education and income were significantly 411 
correlated with each other (polychoric correlation = 0.295, p = <.001; see Appendix Table 2 for 412 
within-survey distributions and associations). Controlling income, respondent education was 413 
significantly and positively associated with treatment overall (3=17.0, p<.001) and in three 414 
service sectors (3=8.9-32.2, p=.030-<.001), the exception being the GM sector. These 415 
significant associations were due to reduced ORs of 0.4-0.8 for respondents in each of the three 416 
lower education categories relative to high-education respondents.  417 
(Table 3 about here)  418 
Family income, in comparison, while not significant overall in predicting any treatment 419 
in a model that controlled for education (3=4.3, p=.233), was significantly and positively 420 
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associated with SMH treatment (3=8.0, p=.045) due to an OR of 0.8 for respondents in each of 421 
the three lower income categories relative to the highest income category. In addition, income 422 
had a significant inverse association with HS treatment (3=9.4, p=.024) due to elevated ORs 423 
for respondents in each of the two lowest income categories (OR=1.5-1.7) relative to the highest 424 
income category.  425 
Interactions of SES with disorder severity, respondent SES, and country income level  426 
Significance of interactions: We estimated interactions of SES with disorder severity 427 
and country income level in predicting any treatment and treatment in the SMH and GM sectors. 428 
We lacked the statistical power to carry out parallel analyses of interactions predicting HS and 429 
CAM treatment. The 3-way interactions were significant for both education and income 430 
predicting any treatment (12=22.9-29.8, p=.029-.003) and for income predicting GM treatment 431 
(12=26.8, p=.008). The 2-way interactions of income with severity and with country income 432 
level were significant in a model that excluded the 3-way interactions in predicting SMH 433 
treatment (6=12.9-13.6, p=.045-.035).  434 
(Table 4 about here)  435 
 Education: Subgroup analysis showed that the significant association of education with 436 
any treatment in the total sample was limited to severe and moderate cases in high-income 437 
countries (3=9.9-17.2, p=.019-.001). Significant ORs among respondents with lower levels of 438 
education were in the range 0.5-0.8. (Table 4) The significant association of education with SMH 439 
treatment in the total sample varied by disorder severity and country income, with significant 440 
ORs among respondents of lower education were in the range 0.6-0.7. The non-significant 441 
association of education with GM treatment found in the total sample was found not to vary 442 
significantly by disorder severity or country income.  443 
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(Table 5 about here)  444 
 Income: Subgroup analysis showed that the non-significant association of income with 445 
any treatment in the total sample masked a significantly positive association among severe cases 446 
in lower-middle income countries (significant ORs of 0.2-0.4 among respondents in lower 447 
income subgroups; 3=20.1, p<.001) and a significantly negative association among mild cases 448 
in upper-middle-income countries (a significant OR=1.8 for low-income respondents; 3=14.9, 449 
p=.002). (Table 5) The significant association of income with SMH treatment in the total sample 450 
was consistent across country income groups due to especially low odds of treatment in 451 
intermediate income groups within each severity subsample (OR=0.3-0.5) rather than in the 452 
lowest income group (OR=0.7-0.9). The non-significant association of income with GM 453 
treatment in the total sample, finally, was found to mask a significantly positive association 454 
among moderately severe cases in lower-middle income countries and mild cases in both lower-455 
middle and high income countries (significant ORs of 0.2-0.7; 3=8.8-18.3, p=.032-<.001) and 456 
significantly negative associations among mild cases in upper-middle-income countries and 457 
severe cases in high income countries (significant ORs of 1.5-2.0; 3=15.1-44.3,, p=.002-458 
<.001).   459 
Discussion 460 
 These results represent the most comprehensive examination ever undertaken of the 461 
associations of SES with mental disorder treatment. Consistent with previous research (Kohn et 462 
al. 2004; Wang et al. 2007; Ormel et al. 2008), only a minority of people with the 12-month 463 
disorders considered here received any treatment, the highest proportion of people receiving 464 
treatment was in the general medical sector followed by the specialty mental health sector, and 465 
treatment was much less common in lower- than higher-income countries. However, the two 466 
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SES indicators considered here, respondent education and family income, were much less 467 
consistently associated with 12-month treatment than we had anticipated.  468 
As noted in the introduction, we had expected to find the association of SES with 469 
specialty treatment to increase with disorder severity to the extent that the restrictions on access 470 
to specialty care were related to income but to decrease with disorder severity to the extent that 471 
the restrictions were related to need for treatment. We found neither pattern, as the lowest odds 472 
of SMH treatment were among respondents having intermediate income levels across all levels 473 
of disorder severity and country income groups. This could be due to lowest-income people, but 474 
not people with intermediate income levels, having free access to specialty care, resulting in 475 
highest financial barriers existing among people with intermediate incomes.  476 
The association of education with SMH treatment was stable across all levels of disorder 477 
severity and country income groups, with the significant association due to a comparatively high 478 
odds of treatment among people at the highest education level (ORs of 0.6-0.7 for lower 479 
education levels equivalent to 1.4-1.7 higher odds at highest versus lower levels). These 480 
associations are presumably not due to financial barriers given that they were obtained after 481 
controlling income. Other possible explanatory variables (e.g., recognition of need, perceived 482 
stigma, perceived efficacy of treatment) need to be explored in future studies to interpret these 483 
associations.  484 
Subgroup analysis found no significant association of income with overall treatment in 485 
the total sample and only inconsistent opposite-sign associations in subsamples. However, the 486 
significant positive association with specialty mental health treatment and the significant inverse 487 
association with human services treatment in the total sample showed that even though people of 488 
different financial means were equally likely to receive some type of treatment, a significant 489 
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discrepancy existed in the sector in which treatment was received. This discrepancy was small, 490 
though, as cases in the highest income category (roughly one-fourth of the population) had only 491 
about 25% higher odds of specialty mental health treatment than those in lower income 492 
categories and, as noted in the prior paragraph, there were no differences in odds of receiving 493 
specialty treatment across the lower three income categories.  494 
Although the association of income with GM treatment was non-significant in the total 495 
sample, a significant 3-way interaction was found due to a series of opposite-sign subgroup 496 
associations that had no apparent patterning. Perhaps the clearest observation about this 497 
specification is that it showed that lowest income was for the most part not associated with 498 
lowest odds of GM treatment. Education, in comparison, was most consistently associated with 499 
SMH treatment, as the associations of education with treatment in other service sectors were 500 
relatively weak (significant ORs in the range 0.6-0.8).  501 
Why did we find weaker and less consistent associations of income and education with 502 
treatment than previous studies (Rossi et al. 2005; Tello et al. 2005; Steele et al. 2007)? One 503 
possibility is that we included two indicators of SES in the models, income and education. Given 504 
that these two indicators are significantly correlated with each other, the strength of each as a 505 
predictor of treatment was reduced by including both in the equations. We considered it 506 
appropriate to include both, though, as the mechanisms involved in the two are presumably 507 
different. As we saw, both indicators were statistically significant, albeit not large in substantive 508 
terms 509 
Limitations 510 
 The study had a number of limitations. First, the sample was limited in that the sample of 511 
countries was non-representative and the response rate varied widely across countries. Although 512 
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we attempted to control for differential response through post-stratification adjustments, survey 513 
response might have been related to social status, presence and severity of mental disorders or 514 
treatment in ways that were uncorrected.  515 
 Second, the disorder measures were limited in that some severe disorders, such as 516 
schizophrenia, were not assessed, duration was not measured for the disorders that were 517 
assessed, and validity, although good in the WMH surveys were it was assessed (Haro et al. 518 
2006), was not assessed in all surveys and might have varied with SES.  519 
 Third, the treatment measures were limited to self-reports, which have been found to 520 
over-estimate treatment compared to administrative records (Rhodes & Fung, 2004). In addition, 521 
these self-reports only assessed number of visits rather than treatment quality. The small amount 522 
of research that exists on mental disorder treatment quality finds that low-SES patients are 523 
significantly more likely than other patients to receive lower-quality treatment (Amaddeo & 524 
Jones, 2007; Young & Rabiner, 2015).  525 
Fourth, the only contextual variable considered was a simple 3-category measure of 526 
country income level. Many other potentially important contextual variable exist at both the 527 
country level (e.g., access to universal healthcare) and within countries (e.g., number of 528 
treatment providers per capita within the access area of the respondent). However, as the number 529 
of countries was small (n = 25) and no information was available about within-country 530 
geographic characteristics in most surveys, we had too few geographic units of analysis to carry 531 
out quantitative analyses of other contextual factors. It might be that future analyses could gain 532 
more insight by estimating within-country models that treated each country as a case study and 533 
considering contextual factors qualitatively.  534 
 535 
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Conclusions 536 
Within the context of these limitations, our findings are consistent with previous research 537 
in showing that only a minority of people with common mental disorders receive treatment, even 538 
in high income countries, and that treatment rates are lower in lower income countries. We also 539 
broadly confirmed previous evidence that people with low SES have an especially low rate of 540 
treatment, although in the total sample this was true only for SMH treatment and income was 541 
inversely related to HS treatment, resulting in income being related more to sector of treatment 542 
than to whether or not treatment was received. The significant associations of SES with 543 
treatment were most consistent in predicting SMH treatment, but they were less strong than 544 
anticipated. Direct investigation of reports about barriers to treatment would be needed to delve 545 
more deeply into these patterns.  546 
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Table 1. Twelve-month treatment of mental disorders overall and within separate service sectors among WMH respondents with 12-month 
DSM-IV/CIDI disorders by survey 
 
Any 
treatment 
 
Specialty 
mental 
health  
 
General 
medical 
 
Human 
services 
 
CAM 
 Number of 
respondents 
with any 
disorder 
 %  (SE)  %  (SE)  % (SE)  % (SE)  %  (SE)  (n) 
I. Lower-middle income countries               
Colombia 13.5 (1.6)  7.4 (1.2)  5.8 (1.0)  1.1 (0.6)  0.5 (0.3)  (789) 
Iraq 11.7 (2.3)  3.6 (1.6)  4.1 (1.4)  4.6 (1.5)  0.5 (0.4)  (469) 
Nigeria 11.7 (2.5)  1.5 (0.8)  10.3 (2.5)  1.3 (0.7)  0.0 (0.0)  (204) 
PRC-Beijing/Shanghai 12.1 (4.5)  3.7 (1.5)  8.5 (4.4)  0.3 (0.3)  4.8 (4.0)  (206) 
PRC-Shenzhen  6.7 (1.6)  2.4 (1.0)  2.6 (0.9)  1.1 (0.7)  2.4 (0.8)  (404) 
Peru 19.1 (2.6)  10.3 (1.4)  5.4 (1.4)  2.7 (0.8)  2.9 (0.9)  (360) 
Ukraine 18.1 (2.3)  4.0 (1.0)  11.1 (1.9)  3.8 (1.0)  1.5 (0.5)  (643) 
Overall  13.7 (0.9)  5.1 (0.6)  6.4 (0.6)  2.6 (0.5)  1.3 (0.3)  (3,075) 
                 
II. Upper-middle income countries                
Brazil-Sao Paulo 24.1 (1.0)  15.5 (1.1)  8.8 (0.8)  3.5 (0.7)  3.4 (0.6)  (1,177) 
Bulgaria 20.7 (2.7)  6.4 (1.2)  16.8 (2.5)  0.9 (0.8)  0.05 (0.05)  (400) 
Colombia-Medellin 18.7 (2.1)  11.7 (1.5)  6.9 (1.4)  1.4 (0.6)  1.6 (0.6)  (514) 
Lebanon 11.0 (1.8)  3.4 (1.1)  7.2 (1.4)  1.2 (0.6)  0.0 (0.0)  (309) 
Mexico 18.0 (1.8)  10.3 (1.5)  6.1 (1.0)  0.6 (0.3)  3.1 (1.0)  (655) 
Romania 23.4 (3.0)  11.2 (2.3)  13.5 (2.7)  0.8 (0.5)  0.0 (0.0)  (175) 
South Africa 25.7 (2.5)  5.8 (1.3)  16.9 (1.9)  6.4 (1.4)  5.8 (1.0)  (700) 
Overall 22.0 (0.9)  10.0 (0.6)  11.3 (0.7)  3.2 (0.5)  3.1 (0.3)  (3,930) 
                 
III. High income countries                 
Belgium 38.3 (4.2)  20.2 (2.8)  30.7 (4.9)  0.9 (0.7)  1.2 (0.6)  (227) 
France 30.5 (2.9)  11.9 (1.6)  23.1 (2.6)  1.5 (0.7)  1.1 (0.6)  (394) 
Germany 25.8 (3.3)  13.5 (2.4)  17.5 (2.7)  1.9 (0.8)  1.2 (0.5)  (268) 
Israel 34.9 (2.3)  17.5 (1.8)  17.3 (1.9)  5.7 (1.1)  3.1 (0.8)  (483) 
Italy 26.7 (2.7)  8.5 (2.2)  22.7 (2.5)  1.2 (0.5)  0.6 (0.4)  (280) 
Japan 22.9 (3.3)  15.3 (2.5)  11.2 (2.1)  1.3 (0.7)  5.5 (2.2)  (237) 
Netherlands 30.5 (4.4)  16.2 (2.9)  24.3 (4.2)  1.7 (0.7)  2.3 (0.8)  (273) 
New Zealand 38.4 (1.2)  16.1 (1.0)  28.4 (1.0)  4.9 (0.5)  6.5 (0.7)  (2,734) 
Northern Ireland 42.5 (3.0)  14.8 (1.8)  38.1 (2.8)  2.7 (0.7)  6.2 (1.4)  (533) 
Poland 21.5 (2.0)  13.5 (1.4)  10.1 (1.2)  2.6 (0.8)  3.7 (0.9)  (622) 
Portugal 36.2 (2.0)  17.6 (1.7)  24.0 (1.7)  2.1 (0.6)  1.7 (0.4)  (726) 
Spain 34.4 (3.1)  20.5 (2.3)  23.1 (2.4)  1.0 (0.5)  1.6 (0.6)  (407) 
Spain-Murcia 49.6 (3.4)  28.0 (4.2)  26.9 (2.6)  0.0 (0.0)  1.0 (0.6)  (361) 
USA 41.6 (0.9)  22.0 (0.9)  23.1 (0.8)  8.1 (0.8)  6.9 (0.6)  (2,203) 
Overall  36.8 (0.6)  17.7 (0.5)  24.2 (0.5)  4.3 (0.3)  4.6 (0.3)  (9,748) 
                 
IV. Total 29.0 (0.5)  13.5 (0.3)  17.8 (0.4)  3.7 (0.2)  3.7 (0.2)  (16,753) 
F2,5366 221.1*  132.7*  231.4*  6.0*  33.2*   
            
*Significant difference across the three country income groups at the .05 level, two-sided test794 
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Table 2. Multivariable associations of clinical characteristics (disorder type, number, and severity) with 12-month treatment of mental disorders overall 
and within separate service sectors among WMH respondents with 12-month DSM-IV/CIDI disorders  (n=16,753)1 
               
 
Any treatment 
 Specialty mental 
health  
 
General medical 
 
Human services 
 
CAM 
 OR (95% CI)  OR (95% CI)  OR (95% CI)  OR (95% CI)  OR (95% CI) 
I. Type of disorder               
a. Anxiety               
Adult separation anxiety disorder 1.1 (0.8-1.4) 1.2 (0.9-1.6) 0.9 (0.7-1.2) 1.2 (0.7-2.0) 1.1 (0.7-1.7) 
Agoraphobia (w/o panic disorder)  1.8* (1.4-2.2) 1.6* (1.2-2.1) 1.9* (1.5-2.5) 0.8 (0.5-1.4) 1.0 (0.7-1.5) 
Generalized anxiety disorder 1.8* (1.5-2.0) 1.6* (1.3-1.9) 1.7* (1.4-2.0) 1.5* (1.1-2.0) 1.4* (1.1-1.9) 
Panic disorder 3.4* (2.8-4.0) 2.4* (1.9-2.9) 3.2* (2.6-3.8) 1.4 (1.0-2.0) 1.4 (0.9-2.0) 
Posttraumatic stress disorder 2.0* (1.7-2.4) 1.7* (1.4-2.1) 1.7* (1.5-2.1) 1.4* (1.0-2.0) 1.7* (1.2-2.3) 
Social phobia 1.1 (1.0-1.3) 1.2* (1.0-1.5) 1.1 (1.0-1.3) 1.1 (0.8-1.6) 1.1 (0.9-1.5) 
Specific phobia 0.9* (0.7-1.0) 0.8 (0.7-1.0) 0.9 (0.8-1.1) 0.8 (0.6-1.1) 1.0 (0.8-1.3) 
b. Mood           
Bipolar spectrum disorder  1.2 (0.9-1.4) 1.3* (1.1-1.7) 1.2 (0.9-1.5) 1.2 (0.9-1.7) 0.9 (0.6-1.3) 
Dysthymic disorder 1.3* (1.1-1.6) 1.1 (0.9-1.4) 1.2 (1.0-1.5) 1.1 (0.8-1.6) 0.7 (0.5-1.1) 
Major depressive episode  2.2* (1.9-2.5) 2.4* (2.0-2.8) 1.9* (1.7-2.3) 1.2 (0.9-1.7) 1.5* (1.1-2.1) 
c. Substance           
Alcohol abuse or dependence 0.7* (0.6-0.9) 1.0 (0.8-1.3) 0.6* (0.5-0.8) 0.7* (0.4-1.0) 0.9 (0.6-1.4) 
Drug abuse or dependence 1.6* (1.2-2.2) 1.6* (1.2-2.1) 1.4 (0.9-2.0) 1.0 (0.6-1.8) 1.8* (1.1-3.0) 
212 506.1*  275.1*  315.1*  39.4*  36.4* 
II. Number of disorders               
4+ 0.7* (0.5-1.0) 0.6* (0.4-0.9) 0.6* (0.4-0.9) 1.1 (0.5-2.1) 1.1 (0.6-2.1) 
3  1.1 (0.9-1.3) 1.0 (0.8-1.3) 1.0 (0.8-1.2) 1.1 (0.7-1.7) 1.3 (0.9-1.9) 
2 1.0 -- 1.0  -- 1.0 -- 1.0 -- 1.0 -- 
22 11.0*  11.7*  9.4*  0.1  1.9 
III. Severity of disorders               
Severe 2.4* (2.1-2.8) 2.9* (2.4-3.4) 2.1* (1.8-2.5) 2.0* (1.5-2.7) 2.4* (1.8-3.3) 
Moderate 1.3* (1.2-1.5) 1.3* (1.1-1.6) 1.4* (1.2-1.6) 1.3 (1.0-1.8) 1.5* (1.1-2.0) 
Mild 1.0 -- 1.0 -- 1.0 -- 1.0 -- 1.0 -- 
22 179.6*  186.0*  90.6*  21.3*  36.6* 
               
*Significant at the .05 level, two-sided test 795 
1Results are based on multivariable logistic regression models with dummy variables for survey. See the section on Analysis Methods in the text for a discussion of the 796 
logic of the models and interpretation of coefficients. 797 
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Table 3. Multivariable associations of socio-demographic characteristics with 12-month treatment of mental disorders overall and within separate service sectors controlling for 
clinical characteristics among WMH respondents with 12-month DSM-IV/CIDI disorders  (n=16,753)1 
     
 Level of education  Level of family income  
 Low Low average High average High 
23 
 Low Low average High average High  
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 23 
I. Any treatment                   
 0.8* (0.7-0.9) 0.8* (0.7-0.9) 0.8* (0.7-1.0) 1.0 -- 17.0*  0.9 (0.8-1.1) 0.9 (0.8-1.0) 0.9 (0.8-1.0) 1.0 -- 4.3 
II. Specialty mental health care              
 0.6* (0.5-0.8) 0.6* (0.5-0.7) 0.7* (0.6-0.9) 1.0 -- 32.2*  0.8* (0.7-1.0) 0.8* (0.7-0.9) 0.8* (0.7-1.0) 1.0 -- 8.0* 
III. General medical           
 1.0 (0.8-1.2) 0.9 (0.8-1.1) 1.0 (0.8-1.2) 1.0 -- 0.6  1.0 (0.8-1.1) 0.9 (0.8-1.1) 0.9 (0.8-1.1) 1.0 -- 1.3 
IV. Human services           
 0.6* (0.4-0.8) 0.8 (0.6-1.1) 0.8 (0.6-1.1) 1.0 -- 8.9*  1.5* (1.0-2.1) 1.7* (1.2-2.4) 1.3 (0.9-1.9) 1.0 -- 9.4* 
V. CAM            
 0.4* (0.3-0.7) 0.7* (0.5-0.9) 0.7* (0.5-0.9) 1.0 -- 19.7*  1.2 (0.9-1.7) 1.1 (0.8-1.5) 1.1 (0.8-1.6) 1.0 -- 1.8 
            
Significant at the .05 level, two-sided test 
1Results are based on multivariable logistic regression models with dummy variables for survey and controls for the clinical variables in Table 2 as well as for respondent age, sex, and marital status. All 
respondents in the French survey were coded at the mean of education because education was not assessed in the French survey 
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Table 4. Subgroup associations of respondent education with 12-month treatment of mental disorders overall and in the specialty 
mental health and general medical sectors based on multivariable models that allowed for interactions of education with disorder 
severity and country income level controlling for clinical characteristics among WMH respondents with 12-month DSM-IV/CIDI 
disorders  (n=16,753)1 
    
 Level of education   
 Low  Low-average  High-average  High   
 OR (95% CI)  OR (95% CI)  OR (95% CI)  OR (95% CI)  23 
I. Any treatment               
A. Lower-middle-income countries            
Severe 2.0 (1.0-4.1)  1.2 (0.6-2.3)  1.4 (0.7-2.9)  1.0 --  4.1 
Moderate 0.9 (0.5-1.9)  1.4 (0.8-2.8)  0.8 (0.4-1.5)  1.0 --  4.0 
Mild 0.5 (0.2-1.1)  0.7 (0.3-1.6)  0.6 (0.3-1.3)  1.0 --  3.1 
B. Upper-middle-income countries            
Severe 0.7 (0.4-1.4)  0.7 (0.4-1.2)  0.9 (0.6-1.6)  1.0 --  2.2 
Moderate 0.8 (0.4-1.5)  0.7 (0.4-1.2)  0.7 (0.4-1.3)  1.0 --  2.3 
Mild 0.7 (0.4-1.4)  0.8 (0.4-1.4)  0.9 (0.6-1.5)  1.0 --  1.5 
C. High-income countries             
Severe 0.5* (0.4-0.7)  0.7* (0.5-1.0)  0.9 (0.7-1.2)  1.0 --  17.2* 
Moderate 0.7* (0.5-0.9)  0.8* (0.6-1.0)  0.8* (0.6-1.0)  1.0 --  9.9* 
Mild 1.4 (1.0-1.9)  0.8 (0.6-1.1)  0.9 (0.7-1.2)  1.0 --  9.2* 
II. Specialty mental health treatment            
Total 0.6* (0.5-0.8)  0.6* (0.5-0.8)  0.7* (0.6-0.9)  1.0 --  31.7* 
III. General medical treatment            
Total 1.0 (0.8-1.2)  1.0 (0.8-1.1)  1.0 (0.9-1.2)  1.0 --  0.4 
              
*Significant at the .05 level, two-sided test 799 
1Results are based on three multivariable logistic regression models, one for each type of treatment. In each model, subgroup coding was 800 
used to estimate associations of education with the outcome in subgroups where the education-treatment outcome was found to be 801 
statistically different from in other subgroups. All models included dummy variables for survey, controls for the clinical variables in Table 2, 802 
and controls for respondent age, sex, marital status, and family income along with any significant interactions of income with disorder 803 
severity and country income level. All respondents in the French survey were coded at the mean of education because education was not 804 
assessed in the French survey.805 
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Table 5. Subgroup associations of respondent family income with 12-month treatment of mental disorders overall and in 
the specialty mental health and general medical sectors based on multivariable models that allowed for interactions of 
education with disorder severity and country income level controlling for clinical characteristics among WMH 
respondents with 12-month DSM-IV/CIDI disorders  (n=16,753)1 
   
 Level of family income  
 Low  Low-average  High-average  High   
 OR (95% CI)  OR (95% CI)  OR (95% CI)  OR (95% CI)  23 
I. Any treatment              
A. Lower-middle-income countries           
Severe 0.4* (0.2-0.8)  0.2* (0.1-0.4)  0.4* (0.2-0.7)  1.0 --  20.1* 
Moderate 0.5* (0.2-0.9)  0.8 (0.4-1.6)  1.0 (0.5-1.9)  1.0 --  7.4 
Mild 1.6 (0.7-3.6)  1.0 (0.4-2.1)  0.8 (0.4-1.9)  1.0 --  2.5 
B. Upper-middle-income countries            
Severe 0.7 (0.4-1.1)  1.0 (0.6-1.6)  1.0 (0.6-1.6)  1.0 --  4.0 
Moderate 0.9 (0.5-1.5)  1.0 (0.6-1.7)  0.8 (0.5-1.3)  1.0 --  1.9 
Mild 1.8* (1.1-3.0)  0.7 (0.4-1.2)  1.3 (0.8-2.3)  1.0 --  14.9* 
C. High-income countries             
Severe 1.0 (0.7-1.4)  1.2 (0.8-1.6)  0.8 (0.6-1.1)  1.0 --  6.4 
Moderate 0.9 (0.7-1.2)  0.9 (0.7-1.2)  1.0 (0.8-1.3)  1.0 --  1.7 
Mild 1.0 (0.7-1.4)  0.8 (0.6-1.1)  0.8 (0.6-1.1)  1.0 --  4.5 
II. Specialty mental health (by severity regardless of country income level)       
Severe 0.7 (0.3-1.4)  0.5* (0.3-0.8)  0.4* (0.2-0.7)  1.0 --  10.9* 
Moderate 0.7 (0.4-1.4)  0.4* (0.3-0.8)  0.5* (0.3-0.8)  1.0 --  11.2* 
Mild 0.9 (0.4-1.9)  0.3* (0.2-0.5)  0.4* (0.2-0.7)  1.0 --  20.2* 
III. General medical treatment            
A. Lower-middle-income countries            
Severe 0.6 (0.3-1.3)  0.5 (0.2-1.0)  0.9 (0.3-2.6)  1.0 --  4.5 
Moderate 0.4* (0.2-0.8)  0.5 (0.3-1.0)  0.8 (0.4-1.7)  1.0 --  8.8* 
Mild 0.4* (0.2-0.9)  0.2* (0.1-0.8)  0.3* (0.1-0.9)  1.0 --  11.0* 
B. Upper-middle-income countries            
Severe 0.6 (0.4-1.1)  1.4 (0.8-2.6)  0.8 (0.5-1.5)  1.0 --  4.8 
Moderate 0.8 (0.5-1.3)  1.4 (0.8-2.2)  0.6 (0.4-1.1)  1.0 --  6.7 
Mild 1.7* (1.1-2.5)  0.5 (0.3-1.0)  0.9 (0.5-1.5)  1.0 --  15.1* 
C. High-income countries             
Severe 1.8* (1.4-2.3)  2.0* (1.6-2.6)  1.5* (1.2-2.0)  1.0 --  44.3* 
Moderate 1.0 (0.8-1.3)  1.0 (0.8-1.2)  1.1 (0.9-1.3)  1.0 --  1.0 
Mild 0.8 (0.6-1.1)  0.6* (0.5-0.8)  0.7* (0.5-0.9)  1.0 --  18.3* 
        
*Significant at the .05 level, two-sided test 806 
1Results are based on three multivariable logistic regression models, one for each type of treatment. In each model, subgroup 807 
coding was used to estimate associations of family income with the outcome in subgroups where the income-treatment outcome 808 
was found to be statistically different from in other subgroups. All models included dummy variables for survey, controls for the 809 
clinical variables in Table 2, and controls for respondent age, sex, marital status, and respondent education along with any 810 
significant interactions of education with disorder severity and country income level. All respondents in the French survey were 811 
coded at the mean of education because education was not assessed in the French survey 812 
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Appendix Table 1.  WMH sample characteristics by World Bank income categoriesa 
     
Sample 
size    
Country by income 
category 
 
 
Surveyb 
 
 
Sample characteristicsc 
 
Field 
dates 
 
Age 
range Part I Part II 
Part II and 
age ≤ 44d 
 
 
Response 
ratee 
I. Low and lower middle income countries       
Colombia NSMH All urban areas of the country (approximately 73% of the total national population)  2003 18-65 4,426 2,381 1,731 87.7 
Iraq IMHS Nationally representative. 2006-7 18-96 4,332 4,332 -- 95.2 
Nigeria NSMHW 21 of the 36 states in the country, representing 57% of the national population. The surveys were conducted in Yoruba, Igbo, Hausa and Efik languages.  2002-3 18-100 6,752 2,143 1,203 79.3 
PRCf - Beijing/Shanghai 
B-WMH/S-
WMH Beijing and Shanghai metropolitan areas. 2002-3 18-70 5,201 1,628 570 74.7 
PRCf  - Shenzheng Shenzhen Shenzhen metropolitan area. Included temporary residents as well as household residents. 2006-7 18-88 7,132 2,475 -- 80.0 
Peru EMSMP Five urban areas of the country (approximately 38% of the total national population). 2004-5 18-65 3,930 1,801 1,287 90.2 
Ukraine CMDPSD Nationally representative. 2002 18-91 4,725 1,720 541 78.3 
TOTAL     (36,498) (16,480) (5,332) 82.2 
II. Upper-middle income countries       
Brazil - São Paulo São Paulo Megacity São Paulo metropolitan area. 2005-7 18-93 5,037 2,942 -- 81.3 
Bulgaria NSHS Nationally representative. 2003-7 18-98 5,318 2,233 741 72.0 
Colombia - Medellinh MMHHS Medellin metropolitan area 2011-12 19-65 3,261 1,673  97.2 
Lebanon LEBANON Nationally representative. 2002-3 18-94 2,857 1,031 595 70.0 
Mexico M-NCS All urban areas of the country (approximately 75% of the total national population).  2001-2 18-65 5,782 2,362 1,736 76.6 
Romania RMHS Nationally representative. 2005-6 18-96 2,357 2,357 -- 70.9 
South Africag SASH Nationally representative. 2003-4 18-92 4,315 4,315 -- 87.1 
TOTAL     (28,927) (16,913) (3,072) 78.5 
III. High-income countries       
Belgium ESEMeD Nationally representative. The sample was selected from a national register of Belgium residents 2001-2 18-95 2,419 1,043 486 50.6 
France ESEMeD Nationally representative. The sample was selected from a national list of households with listed telephone numbers.  2001-2 18-97 2,894 1,436 727 45.9 
Germany ESEMeD Nationally representative.  2002-3 19-95 3,555 1,323 621 57.8 
Israel NHS Nationally representative. 2002-4 21-98 4,859 4,859 -- 72.6 
Italy ESEMeD Nationally representative. The sample was selected from municipality resident registries. 2001-2 18-100 4,712 1,779 853 71.3 
Japan WMHJ 2002-2006 Eleven metropolitan areas.  2002-6 20-98 4,129 1,682 -- 55.1 
Netherlands ESEMeD Nationally representative. The sample was selected from municipal postal registries. 2002-3 18-95 2,372 1,094 516 56.4 
New Zealandg NZMHS Nationally representative. 2003-4 18-98 12,790 7,312 -- 73.3 
N. Ireland NISHS Nationally representative. 2004-7 18-97 4,340 1,986 -- 68.4 
Poland EZOP Nationally representative 2010-11 18-65 10,081 4,000 2,276 50.4 
43 
 
Portugal NMHS Nationally representative. 2008-9 18-81 3,849 2,060 1,070 57.3 
Spain ESEMeD Nationally representative. 2001-2 18-98 5,473 2,121 960 78.6 
Spain - Murcia PEGASUS- Murcia Murcia region. Regionally representative.  2010-12 18-96 2,621 1,459 -- 67.4 
United States NCS-R Nationally representative. 2002-3 18-99 9,282 5,692 3,197 70.9 
TOTAL     (73,376) (37,846) (10,706) 62.9 
IV. TOTAL     (138,801) (71,239) (19,110) 70.1 
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 818 Appendix Table 2. Within-survey distributions and associations (polychoric correlations) between level of education and level of family income among WMH respondents with 12-month DSM-IV/CIDI disorders (n = 16,753) 
 
 Level of education1 Level of family income2  
 Low  Low-average 
 High High-average Low 
Low-
average High 
 High-
average  
 % (SE)  % (SE)  % (SE) % (SE) % (SE) % (SE) % (SE)  % (SE) r*2 
I. Lower-middle income countries                   
 Colombia 30.0 (2.5)  29.3 (2.6)  19.5 (1.6) 21.2 (2.5) 35.2 (2.9) 24.8 (2.8) 16.6 (1.9)  23.3 (2.7) 0.405*
 Iraq 20.6 (3.2)  36.9 (3.8)  32.5 (3.2) 10.1 (1.8) 27.0 (3.0) 24.8 (2.8) 23.1 (2.7)  22.7 (3.9) 0.269*
 Nigeria 19.5 (3.7)  21.3 (4.6)  43.1 (4.6) 16.1 (4.5) 39.7 (5.4) 15.7 (3.5) 18.6 (4.5)  26.0 (4.2) 0.284*
 PRC-Beijing/Shanghai 16.4 (5.6)  21.1 (3.8)  39.7 (5.3) 22.8 (5.0) 21.4 (4.4) 33.9 (6.0) 27.4 (5.2)  17.3 (4.5) 0.328*
 PRC-Shenzhen 1.9 (0.8)  19.6 (3.0)  40.6 (3.9) 37.9 (3.1) 29.9 (2.9) 18.8 (2.4) 21.6 (2.9)  29.7 (3.9) 0.389*
 Peru 13.4 (1.8)  11.0 (2.0)  58.9 (3.1) 16.6 (2.8) 37.3 (2.6) 21.1 (2.4) 20.0 (2.4)  21.5 (3.8) 0.519*
 Ukraine 17.3 (2.4)  52.9 (2.7)  14.6 (2.7) 15.2 (2.3) 18.2 (2.3) 35.2 (2.9) 34.5 (2.8)  12.1 (2.5) 0.192*
 Overall 19.4 (1.2)  31.3 (1.3)  31.0 (1.3) 18.3 (1.0) 29.5 (1.2) 26.1 (1.2) 22.9 (1.1)  21.5 (1.4) 0.324*
                  
II. Upper-middle income countries                
 Brazil-Sao Paulo 24.2 (1.6)  24.7 (1.5)  35.4 (1.8) 15.6 (2.0) 25.3 (1.8) 27.3 (2.0) 23.8 (1.7)  23.6 (2.6) 0.419*
 Bulgaria 10.3 (2.1)  23.0 (3.0)  41.8 (4.0) 25.0 (4.3) 16.9 (2.1) 30.2 (3.3) 27.6 (3.1)  25.3 (4.4) 0.389*
 Colombia-Medellin 2.1 (0.6)  22.2 (2.4)  48.0 (3.0) 27.8 (2.9) 41.7 (3.0) 18.1 (2.3) 20.8 (2.4)  19.5 (2.5) 0.211*
 Lebanon 21.2 (4.8)  33.4 (3.9)  28.7 (5.0) 16.7 (3.3) 29.0 (4.2) 21.7 (4.2) 17.1 (4.8)  32.2 (4.5) 0.240*
 Mexico 20.7 (2.3)  23.0 (2.2)  29.5 (2.4) 26.7 (2.8) 29.9 (2.8) 27.3 (2.2) 19.4 (1.8)  23.4 (2.0) 0.393*
 Romania 10.9 (2.2)  21.1 (2.6)  51.9 (3.1) 16.1 (2.9) 32.0 (4.5) 17.0 (3.7) 20.9 (3.3)  30.1 (4.5) 0.234*
 South Africa 6.1 (1.1)  23.1 (2.1)  54.7 (2.4) 16.2 (2.0) 41.7 (3.2) 10.2 (1.3) 11.6 (1.7)  36.4 (3.3) 0.329*
 Overall 14.4 (0.8)  24.0 (0.8)  42.3 (1.1) 19.3 (0.9) 31.8 (1.0) 21.1 (0.8) 19.5 (0.9)  27.7 (1.1) 0.313*
                 
III. High income countries                 
 Belgium 10.0 (2.3)  13.1 (2.8)  49.4 (5.3) 27.4 (4.3) 22.5 (4.6) 25.7 (3.4) 36.4 (5.1)  15.4 (2.6) 0.127*
 France -- --  -- --  -- -- -- -- 30.0 (4.4) 31.5 (3.7) 24.1 (2.7)  14.4 (2.9) -- 
 Germany 23.5 (4.2)  32.1 (4.8)  39.5 (6.4) 4.9 (2.4) 26.1 (3.9) 28.5 (4.0) 30.7 (3.6)  14.8 (2.6) -0.030
 Israel 27.4 (2.1)  40.6 (2.4)  12.6 (1.6) 19.4 (1.9) 32.4 (2.3) 27.9 (2.2) 27.9 (2.1)  11.9 (1.5) 0.399*
 Italy 31.9 (4.3)  17.1 (2.7)  33.6 (3.5) 17.4 (3.4) 22.6 (3.4) 25.6 (2.7) 32.8 (3.8)  19.0 (4.2) 0.184*
 Japan 15.4 (2.4)  29.9 (3.5)  28.2 (3.7) 26.5 (4.1) 31.1 (3.9) 24.1 (3.3) 31.1 (3.5)  13.7 (2.1) -0.023
 Netherlands 23.8 (3.9)  41.4 (4.5)  9.7 (1.8) 25.1 (3.4) 30.8 (5.6) 25.0 (3.3) 30.6 (3.6)  13.5 (2.5) 0.366*
 New Zealand 19.7 (1.1)  22.7 (1.0)  29.5 (1.3) 28.1 (1.4) 26.2 (1.4) 30.5 (1.2) 28.2 (1.3)  15.1 (1.0) 0.261*
 Northern Ireland 4.7 (1.0)  9.5 (1.6)  70.9 (2.7) 14.8 (2.1) 28.6 (2.8) 25.2 (2.9) 25.4 (1.9)  20.9 (3.0) 0.153**
 Poland 10.9 (1.6)  3.5 (1.1)  67.7 (2.2) 17.9 (2.0) 41.5 (2.6) 12.9 (1.6) 24.1 (2.0)  21.6 (2.0) 0.217**
 Portugal 20.9 (1.6)  33.0 (2.0)  26.7 (2.2) 19.5 (1.7) 31.3 (2.4) 16.8 (1.8) 25.5 (2.7)  26.5 (2.3) 0.357**
 Spain 22.0 (3.1)  34.1 (4.4)  16.8 (2.7) 27.1 (4.6) 24.5 (4.5) 26.0 (4.6) 30.9 (3.9)  18.6 (3.2) 0.219**
 Spain-Murcia 23.0 (3.3)  35.2 (4.0)  21.5 (2.8) 20.3 (3.8) 31.2 (4.2) 32.3 (3.1) 25.0 (2.8)  11.5 (2.4) 0.198**
 USA 18.4 (1.3)  32.9 (2.3)  29.0 (1.3) 19.7 (1.5) 30.3 (1.7) 25.4 (1.2) 26.0 (1.4)  18.3 (1.4) 0.434**
 Overall 18.0 (0.5)  25.5 (0.7)  35.7 (0.7) 20.7 (0.6) 29.5 (0.7) 26.0 (0.6) 27.3 (0.7)  17.2 (0.5) 0.280**
                   
Total 17.4 (0.4)  26.1 (0.5)  36.6 (0.6) 19.9 (0.5) 30.1 (0.5) 24.8 (0.5) 24.5 (0.5)  20.6 (0.5) 0.295**
                     
*Significant at the .05 level, two-sided test 
1See the text for a description of the coding rules for the categorical measures of education and income.  
2Polychoric correlations 
3All respondents in the French survey were coded at the mean value of the education distribution across other surveys because education 
was not assessed in the French survey. 
